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Abstract Genetically modified (GM) plants are increasingly
used for food production and industrial applications. As the
global population has surpassed 7 billion and per capita
consumption rises, food production is challenged by loss
of arable land, changing weather patterns, and evolving
plant pests and disease. Previous gains in quantity and
quality relied on natural or artificial breeding, random
mutagenesis, increased pesticide and fertilizer use, and
improved farming techniques, all without a formal safety
evaluation. However, the direct introduction of novel
genes raised questions regarding safety that are being
addressed by an evaluation process that considers
potential increases in the allergenicity, toxicity, and
nutrient availability of foods derived from the GM
plants. Opinions vary regarding the adequacy of the
assessment, but there is no documented proof of an
adverse effect resulting from foods produced from GM
plants. This review and opinion discusses current
practices and new regulatory demands related to food
safety.
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Introduction
Development and adoption of genetic engineering to
introduce a foreign gene to create a functionally distinct,
genetically modified (GM) plant has been one of the most
rapidly adopted technologies in the history of agriculture
[1]. The technology allows the introduction of one or a few
individual genes from any living organism into the genome
of the recipient plant, whereas traditional breeding requires
sexually compatible gene sources and acceptors and trans-
fers thousands of genes, including undesirable genes [1].
Global cultivation of commercial GM crops began in 1996
with approximately 4.3 million acres, then expanded to
more than 335 million acres (134 million hectares) by 2009
[2]. Since 1994, regulators in the United States have
approved many GM events of insect pest–resistant corn,
cotton, and potatoes; herbicide-tolerant canola, corn, cotton,
and soybeans; and virus-resistant papayas, potatoes, and
squash that have been evaluated for food, feed, and
environmental safety [3]. Most of the genes introduced
into GM plants encode proteins that are expressed at low
levels (10–500 ppm; <0.2% of total protein) and either have
a history of safe use or are similar to commonly consumed
proteins [4]. Insecticidal cry 1A genes were transferred from
a bacterium that has been commonly used by organic
farmers. The glyphosate (herbicide)-tolerant enzyme intro-
duced into soybeans is very similar to enzymes in nearly all
bacteria and green plants. These plants require fewer
pesticide applications or provide options for weed and
disease control. A few introduced genes encode an
antisense RNA that blocks viral infection or inhibits
expression of specific endogenous plant genes without
expression of any new protein [5]. Approximately 15.4
million farmers grew approved GM crops on 148 million
hectares in 29 countries in 2010, representing 81% of
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soybean, 64% of cotton, 29% of corn, and 23% of canola
cultivation [2].
Development and testing of a new GM crop typically
requires 8 to 12 years, including more than 4 years of safety
and environmental testing, before regulatory approval and
commercial release. Because there is no global approval
and registration process for foods derived from GM
organisms, approvals are country specific, and testing
requirements sometimes differ. However, the Codex
Alimentarius Commission (Codex), under the Food and
Agriculture Organization and the World Health Organiza-
tion of the United Nations, attempts to harmonize food
safety testing to protect human health while facilitating
international trade. The Codex food safety guideline for
GM plants was published in 2003 and includes a
comprehensive assessment of potential allergenicity [6].
Regulations in the United States follow Codex guidelines
and are administered by the US Food and Drug Admin-
istration (FDA), which has overall responsibility for food
safety, while the Environmental Protection Agency shares
responsibilities in evaluating food safety of GM crops that
produce insecticidal proteins or antiviral or antifungal
products [7]. The European Food Safety Authority
(EFSA), a scientific advisory panel for European regu-
lators, published food safety guidelines for GM plants in
2004 [8]. However, the European Union (EU) has been
slow to approve any GM crops, even though tests
demonstrate that they meet international safety standards
and have been marketed in other countries for many years.
Currently, the EU only allows cultivation of one potato
and two corn (maize) GM events, and the importation of
food or feed from less than half of the GM varieties
accepted in the United States [9].
Testing and registration requirements should be clear.
However, during the past 14 years, we have observed an
increasing number of publications describing scientifically
unsound studies, as well as demands by international
regulators (or scientific advisors) for studies and tests that
are not based on clear principles of risk assessment. In our
opinion, these tests do not improve safety but do increase
the chance of rejecting potentially useful products.
Food Safety
No food is safe for all consumers at all levels of
consumption, even when prepared by traditional methods.
Approximately 1% of the global population has celiac
disease and must avoid foods containing wheat, barley, or
rye grains. Those with food allergies must avoid the
specific food(s) that elicit their symptoms. Navy beans
and kidney beans (Phaseolus vulgaris) must be boiled for
approximately 10 min to inactivate the abundant lectin
phytohemagglutinin in order to avoid intestinal bleeding
and discomfort. The guiding principle for GM safety since
the early-1990s is that foods prepared using the new GM
variety should be as safe as those prepared using the non-
GM counterpart [6].
Risk assessment food safety involves four main compo-
nents: hazard identification, hazard characterization, expo-
sure assessment, and risk characterization [10, 11]. The
primary focus for GM crop safety is on evaluating the
potential toxicity of the protein or metabolites of GM
enzymes and the allergenicity of the introduced protein(s)
based on the extensive historical knowledge of toxins and
allergens and proven test methods [12••, 13••]. The risk
assessment process should provide information to guide
regulators regarding identification of any hazard (allergen
or cross-reactive protein), characteristics of the at-risk
population (those with specific allergies), risk severity,
and information to estimate exposure [14, 15].
Allergenicity Assessment
Essentially any protein could be allergenic for at least one
person if administered with an IgE-inducing adjuvant.
However, everyone is exposed to hundreds of thousands
of proteins during his or her lifetime that do not sensitize or
elicit allergic reactions. The risk associated with an allergen
is for those who have been sensitized to a protein causing
the production of protein-specific IgE antibodies that can
elicit an allergic reaction. Individuals who are not sensitized
are not at risk, and some who are sensitized will never
experience an allergic reaction. The risk of allergy from
traditional foods can only be managed if allergic individuals
and their families know the identity of the food that causes the
allergy, if the foods they consume are prepared without the
allergen, and if they have reliable information about food
ingredients in processed foods and in restaurants to enable
avoidance. To be effective, the allergenicity assessment of
GM crops must focus on the same risks of food allergy as
posed by traditional foods. The primary goal is to prevent the
transfer of an existing allergen or celiac-inducing protein into
a new food source and to protect those who are allergic or
have celiac disease.
The overall prevalence of food allergy in North America
is approximately 6%, while less than 1% are allergic to
peanut, one of the most commonly cited and potent
allergenic foods [16]. Food allergy is caused by a small
number of proteins in even the most commonly allergenic
foods, such as peanuts, tree nuts, fish, milk, or eggs. People
allergic to the same food may react to different proteins. It
is not possible to predict who will become allergic or to
which foods or proteins they will become allergic. Many
countries now require clear labeling of a food’s major
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ingredients as well as refined ingredients from the major
allergenic sources. Food companies go to great lengths to
segregate and label allergenic ingredients that are included
in packaged foods. However, accidents still occur from
foods obtained from commercial packages, restaurants, and
homes of friends and family members. Studies have
estimated that 100 to 200 fatal reactions occur in the
United States when allergic consumers are unexpectedly
exposed to the food that causes their allergy (usually peanut
or a tree nut), and that there are more than 100,000 visits to
a hospital emergency department, in addition to mild
reactions for which medical care was not sought [16, 17].
The Codex guideline on the allergenicity assessment of
GM plants begins with an evaluation of the history of
human exposure to the source of the gene and considers
whether there is evidence of allergy associated with the
protein or the source [6, 13••]. A similar risk is posed by
proteins that are similar enough in sequence and structure to
a food allergen that IgE from the allergic individual can
bind and elicit an allergic reaction upon first exposure to the
similar protein [13••, 18, 19]. Genes taken from wheat or
relatives of wheat are also evaluated to ensure that they will
not induce celiac disease [6]. The amino acid sequence of
the new protein is compared with those of known allergens
to determine whether the protein is already known to be
allergenic or is so similar to an allergen (probably >50%
identical) that cross-reactivity is possible. If the source or
sequence comparison suggests possible risk, sera from
appropriately allergic individuals should be tested for
specific IgE binding and, if indicated, biological activity
[13••]. In addition, the characteristics commonly associated
with proteins that are important food allergens are evaluated
to consider possible de novo sensitization or elicitation (if
sensitized). Similar evaluations were performed prior to
2003 based on earlier guidelines [7, 16]. The assessment
strategy worked well to identify and stop development of
the only publicly identified potential product to date that
would have presented a clear risk of allergy to a population
of tree nut–allergic individuals [20]. However, some
uncertainties exist. Allergies to some sources are so rare
that donors cannot be identified to perform serum tests.
Furthermore, the predictive values of biochemical charac-
teristics, including protein stability in pepsin and abun-
dance, are not known. There are stable and abundant
dietary proteins that do not cause allergy, as well as labile
and moderately abundant proteins that do cause food
allergy. Although improvements are possible, it is also
important to consider that when any individual begins
consuming a traditional food, there is a risk of sensitization
and allergy.
The current allergenicity assessment could be strengthened
by an explanation of probable hazards and a description of
who is at risk and how exposure and risk assessment should
be evaluated. The lack of clarity has led some scientists and
regulators to search for methods enabling perfect predictions
or to demand additional unproven tests or modification of test
methods without validation. Additionally, the concept of
“substantial equivalence” of GM plants relative to similar
varieties of non-GM plants is often interpreted to mean
any statistically significant difference is unacceptable. In
the context of allergenicity, scientists and regulators want
to see results showing no increased expression of
endogenous allergens at least for commonly allergenic
crops such as soybean [6, 8]. However, natural variation
across non-GM varieties is not documented, and the
influence of environmental factors often will yield modest
to marked differences in the expression of a wide variety
of proteins, including allergens. More importantly, some-
one who is allergic to a food should avoid consumption of
that food. Those without allergy can consume the food at
will. Where is the risk?
Source of the Gene
The identity of the source of the introduced gene must be
revealed, and literature related to human exposure and risk
should be thoroughly reviewed. The information is essential
to consider whether the protein may be an allergen, or
whether there is an established “history of safe use”
(HOSU) for the source and the protein. The HOSU is
defined differently by various regulatory agencies [21]. The
EU (1997) requires documentation of extensive use prior to
May 1997 for HOSU. The FDA (1997) defines foods or
food ingredients as GRAS (generally recognized as safe)
only if commonly consumed prior to January 1, 1958. In
our opinion, the definition of HOSU for the allergenicity
assessment should be based on more current data and
knowledge of allergy and allergens. Few allergens were
well-defined before 1990. The evaluation should address
two questions. First, was the gene encoding the GM protein
isolated from an important source of allergy, including
foods, pollen, arthropods, animal dander, latex, insect
venom, or mosquito saliva? Second, is there documentation
that humans have been exposed to the protein without any
evidence of allergenicity?
Many allergenic proteins have been identified in the past
20 years, and recent publications typically describe more
definitive evidence compared with 1990. Although allergenic
protein sources contain hundreds to thousands of proteins,
only a few proteins from any one source are demonstrated to
be allergens. Many are now listed in allergen-specific
databases (eg, AllergenOnline from the Food Allergy Re-
search and Resource Program at the University of Nebraska
[22] and the International Union of Immunological Societies
Allergen Nomenclature database [23]).
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Bioinformatics Search Comparison to Allergens
Allergens and cross-reactive proteins cannot be identified
by structure or sequence similarity alone. Although the
biochemical structure and function of many allergenic
proteins may be classified into a few protein families,
many members of those families are not allergens, and
many allergens belong to diverse families [24]. Although
sequence comparisons will not predict three-dimensional
structures or IgE-binding sites (epitopes), it is clear that
similar overall three-dimensional structures require rela-
tively good sequence conservation and that the sequence
alignment tools of BLAST (Basic Local Alignment Search
Tool) or FASTA can easily match proteins that are
sufficiently similar to suspect shared cross-reactivity
[25]. An overall sequence identity alignment of proteins
sharing greater than 70% suggests cross-reactivity, where-
as proteins sharing less than 50% identity are unlikely to
share IgE cross-reactivity [26]. Although identity matches
of less than 50% are unlikely to share IgE binding, lower
alignment score criteria have been used as a threshold to
trigger serum IgE testing to evaluate potential cross-
reactivity [27••]. An appropriate assessment requires a
well-curated database as well as alignment tool and
appropriate criteria [25].
Allergenic Protein Databases
The 1996 publication by Metcalfe et al. [18] only listed
150 allergenic proteins. Version 11 (February 2011) of our
peer-reviewed AllergenOnline database lists amino acid
sequences of 1,491 allergenic proteins, including isoforms
from 553 taxonomic-protein groups (protein types listed
by species) [22]. The sequences were selected from more
than 24,000 sequences labeled with the keyword “aller-
gen” from the 13 million protein sequence entries in the
public protein database at the National Center for
Biotechnology Information [28]. The review of publica-
tions describing the proteins and evidence of IgE binding
and allergenicity is used to remove National Center for
Biotechnology Information entries that are from allergenic
organisms but without proof of allergy for the protein, and
those listed as allergens only because of sequence
similarity to an allergen. The other available databases
are not updated regularly or do not list clear selection
criteria for inclusion [25]. Some scientists have suggested
searching for specific IgE-binding sequences (epitopes)
rather than whole sequences, but the validity of most
“epitopes,” including many of those in the Immune
Epitope Database from the La Jolla Institute of Allergy
and Immunology [29], have not been verified as IgE or
allergenic epitopes.
Bioinformatics Search Tools and Criteria
Metcalfe et al. [18] proposed using a FASTA local sequence
alignment tool developed by W. Pearson of the University
of Virginia to compare the amino acid sequence of the
introduced GM protein with those of known allergens to
identify probable homologues. Then alignments were
further evaluated to identify matching segments of eight
contiguous amino acids as plausibly representing shared
epitopes (B-cell–/IgE-binding sites or T-cell epitopes) that
might elicit cross-reactions. They recommended using sera
from individuals allergic to the matched allergen to test for
possible cross-reactivity. However, the description of their
method was ambiguous, and subsequent regulatory studies
have typically used a simple “word” search to identify
matches of eight contiguous amino acids without consider-
ation of homology, which likely overpredicts potential
cross-reactivity [25]. A later recommendation by an expert
panel suggested reducing the length of the identity matches
from eight to six, but without any validation [30]. Several
authors challenged the short amino acid identity match as
providing primarily false-positive identities as well as
missing potentially cross-reactive matches [27••, 31, 32].
A slightly less conservative criterion of greater than 35%
identity over 80 or more amino acids using FASTA or
BLASTP was also proposed by the Food and Agriculture
Organization and the World Health Organization of the
United Nations panel and was accepted by Codex [6, 33].
The FASTA approach with a criterion of greater than 35%
identity identifies fewer false-positive matches and thus far
does not seem to have missed any known cross-reactive
matches [13••, 33]. Although some regulators continue to
rely on the short amino acid criterion, there are no data to
demonstrate a positive predictive value in the absence of
extensive homology. Regulators in Asia have insisted that
three GM products approved in the United States be tested
for serum IgE binding due to short amino acid matches.
Serum IgE binding did not show cross-reactivity between
Cry 1 F and the house dust mite allergen Der p 7 that shares
an isolated seven amino acid match [34]. Two other GM
proteins have been tested for serum IgE cross-reactivity
based on isolated eight amino acid matches, and results for
both studies were negative (personal communication with
one developer; unpublished results from our laboratory).
However, those studies were complicated, time consuming,
and expensive, and results of IgE binding are often difficult
to interpret because of low-level nonspecific or irrelevant
IgE “binding” [35–37]. Because the purpose of the
bioinformatics search is to identify matches that may
require further evaluation by IgE binding, full-length
sequence evaluation or an increase in the threshold from
35% identity toward 50% for the 80 amino acid alignment
should be considered [27••, 38].
320 Curr Allergy Asthma Rep (2011) 11:317–324
A few potential GM products have been described in the
literature that present matches of greater than 35% identity
over 80 amino acids to allergens. Those products should be
tested by specific serum IgE binding if they were intended
for commercial use [13••]. The gene of α-amylase inhibitor
from common bean was introduced into field peas to
protect against the storage beetle, which often causes a high
percentage of loss [39]. The protein sequence of α-amylase
inhibitor is slightly more than 40% identical to peanut
agglutinin, a minor allergen of peanut. Serum IgE-binding
studies are in progress in our laboratory to test for cross-
reactivity, but to date, only 1 serum from 34 peanut-allergic
individuals had clear and specific IgE binding to peanut
agglutinin, and that serum did not bind to α-amylase
inhibitor (unpublished results). Serum IgE from a few
patients with high IgE binding to cross-reactive carbohy-
drate determinants (CCDs) on phytohemagglutinin and
other glycoproteins bound to the α-amylase inhibitor due
to CCDs. The IgE binding was inhibited by preincubat-
ing the sera with nonhomologous CCD proteins. Addi-
tional tests are being performed to evaluate the ability of
α-amylase inhibitor to activate basophils that are sensi-
tized with IgE from peanut-allergic individuals or those
with CCD binding, but thus far, results are negative
(unpublished).
Some criticize the use of bioinformatics, as it has
limited our ability to predict the allergenicity (rather than
potential cross-reactivity) of a test protein [40]. However,
no single test can predict allergenicity a priori, and the
intent is merely to identify proteins that present a potential
risk of cross-reactivity and require specific serum tests for
verification [27••].
Jank and Haslberger [41] advocated the use of algo-
rithms that predict antigenic epitopes. However, to date, no
algorithms have proven predictive for allergenicity, and
antigenicity predictions are not accurate. Others have tried
to use peptide mimotopes to predict cross-reactivity [42], or
allergenic motifs based on protein dimension vector
calculations to predict possible epitope similarity [43], but
those methods and databases have not been widely tested
for prediction accuracy [33].
In Vitro IgE-Binding Tests
Antigen-specific IgE-binding assays should be performed
when the source of the gene is commonly allergenic, or
when the bioinformatics search identifies a significant
match to a known allergen [6, 7, 18, 27••]. Various test
formats may present proteins in conformations that are not
equivalent. Native protein epitopes may be presented in
enzyme-linked immunosorbent assay (ELISA) or native gel
immunoblots. Proteins separated in sodium dodecyl-sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) or SDS-
PAGE with reducing agent (β-mercaptoethanol) should
present sequential and some conformational epitopes. More
than one method should be used. The GM protein, the
suspected allergen (source or sequence matched), and other
control proteins should be included to evaluate specificity
of binding. In addition, reciprocal inhibition tests are
needed to determine the specificity of IgE binding [37]. In
vitro IgE binding may be due to the presence of a single
epitope or low-avidity binding and may not allow effective
IgE cross-linking on mast cells and basophils [19]. The
biological importance of IgE binding may be tested further
by in vitro basophil histamine release or in vivo via skin
prick tests [44].
Protein Stability in Pepsin and Processing
General observations that many important food allergens
are stable to digestion by pepsin, and some are still able to
elicit an allergic response after cooking led to the reliance
on those properties as indicators that a given food protein is
likely to sensitize some consumers [6, 17]. However, it is
likely that those characteristics are related to the ability of
some proteins to elicit systemic allergic reactions rather
than sensitization. Although the predictive value of the
pepsin assay can be debated, tests using uniform, standard-
ized conditions with pH at 1.2 or 2.0 and a fixed ratio of
pepsin activity to test protein provide a relatively good
correlation for allergenicity [45–47]. Tests to measure the
stability of the protein under heating conditions are
frequently requested by regulators. However, the conditions
for heating or processing are not standardized, and there are
no clear hypotheses or test methods that allow standardiza-
tion. It is also clear that some highly stable proteins do not
cause food allergy [47]. The abundance of food allergens
suggests a plausible relationship for risk assessment, as
many food allergens represent 1% or more of the total
protein in the food ingredient [45]. However, as some
highly allergic individuals react to milligram amounts of
some allergenic proteins, no consensus exists regarding a
lower limit of concern.
Evaluating Potential Changes in Endogenous Allergen
Content
There are few data documenting normal variation of the
expression levels of various allergenic proteins for currently
used varieties of most crops. However, most regulators
expect a relative comparison of IgE binding to a new GM
soybean and genetically similar non-GM varieties of
soybean because soybean is considered a commonly
Curr Allergy Asthma Rep (2011) 11:317–324 321
allergenic crop. Testing requirements from the EFSA
recently have increased markedly [13••]. Our laboratory
has conducted studies for biotechnology developers to meet
EFSA requirements for IgE binding to immunoblots from
both one-dimensional and two-dimensional gel electropho-
resis–separated soybean proteins using multiple individual
allergic sera as well as inhibition ELISA tests (unpublished
results). However, no clear limits have been established for
acceptance or rejection. Minor differences were noted but
were similar to differences between other commercial
soybean varieties. Some regulators are now asking for
similar tests to evaluate new GM varieties of rarely
allergenic crops such as corn (maize). Because those with
allergies should avoid their allergen, the requirement to test
for differences in expression is not relevant to safety.
Recently, some scientists who have been involved as
advisors to regulators of GM products have performed
comparative proteomics tests or animal antigenicity tests on
previously approved GM products without describing a
testable hypothesis or end points of acceptability. Mon-
santo’s (St. Louis, MO) insect-protected GM corn event
(MON810) was approved in 1996 but was the subject of
two European studies of questionable merit [48, 49]. The
first study looked for changes in the proteome by replicate
two-dimensional gel electrophoresis and staining of sam-
ples of MON810 in a background of DKC6575, compared
with its “non-transgenic near-isogenic line” (identity not
disclosed). The authors found as many differences between
replicates as from the GM to non-GM. Rather than
conclude that there was no biologically significant differ-
ence, the authors discussed the complexity of the tests and
data interpretation and suggested that even more detailed
studies are needed for “accurate safety evaluation of crop
plants using Omics technologies.” Similarly, Adel-Patient et
al. [49] dosed mice with purified Cry 1Ab and with
MON810 to look for immune responses and metabolic
changes. After seeing no significant changes, they still
concluded that further tests are needed to evaluate potential
unintended effects. Although regulatory guidelines recom-
mend evaluating new GM plants for potential increases in
allergen content [6, 8], they ignore recent published
information that demonstrates serum IgE binding differs
more than twofold in some patients across non-GM crop
varieties [13••].
Animal Models
Several guidance documents and publications have sug-
gested using animal models to predict sensitizing potential
and allergenicity, but they also recognize that current
models have not been demonstrated to predict which food
proteins cause allergy in humans [6, 8, 13••]. Although a
validated animal model would be useful to help evaluate
the potential risk of de novo sensitization, test results in
several species (mice, rats, dogs, guinea pigs, and swine)
have failed to provide consistent results with fixed
sensitization protocols for accurately predicting human
responses [50].
Past Experiences for the Allergenicity Assessment
of Genetically Modified Plants
The assessment process has proven effective at identifying
the only potential GM variety that has been publically
disclosed, which would have caused a real risk of allergy to
specifically allergic consumers [20]. A few other GM crops
under development may pose some risk of allergy based on
our evaluation of published information, but those are
unlikely to pass regulatory assessment without additional
serum IgE testing to demonstrate a low probability of risk.
Some uncertainties still exist based on imperfectly predict-
able testing. The pepsin-stable Cry 9 C protein in StarLink
(Bayer CropScience AG, Monheim, Germany) corn prob-
ably posed little risk, as expression of the protein in seed
was approximately 50 ppm in corn grain. However,
regulators have yet to articulate a policy to integrate data
on stability and abundance to provide acceptance criteria.
Conclusions
In our opinion, most current allergenicity assessment
procedures for GM food crops are based on the best
available science. There is no published evidence of allergic
reactions to any GM protein or any adverse human health
reactions associated with consumption of foods from GM
crops during the past 14 years. However, the allergenicity
assessment by most countries should be updated to
emphasize the priorities of hazard identification, risk
characterization, and exposure. It should center on protect-
ing those with existing allergy from unexpected exposure to
an allergen or proven cross-reactive protein focusing on: (1)
evaluation of the history of safety (or risk) of the source of
the gene, (2) sequence comparison of the GM protein to
known allergens by FASTA or BLAST to identify matches
of greater than 35% (or higher) identity over alignments of
at least 80 amino acids, and (3) specific serum IgE-binding
tests to be performed only if the source of the gene is a
common allergen or the sequence matches an allergen (step
two). Evaluation of de novo sensitization should be
improved after further study to optimize and integrate
information on the stability of the protein in pepsin and the
abundance of the protein in food. Any requirement for
additional tests, including evaluation of potential changes in
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endogenous allergen expression, should be weighed care-
fully to ensure methods are scientifically valid and end
points are established that have biological meaning. Based
on current evidence, consumers should feel confident that
approved GM crops are as safe as traditional crops, and
scientists should consider limiting studies to those that are
predictive of food safety.
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